These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32564753)

  • 1. Intravesical Botox for Overactive Bladder: How to Minimize Complications and Manage Failures.
    Apostolidis A; Papaefstathiou E; Gatsos S
    Curr Drug Targets; 2020; 21(15):1527-1536. PubMed ID: 32564753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis.
    Chen JL; Kuo HC
    Investig Clin Urol; 2020 Feb; 61(Suppl 1):S33-S42. PubMed ID: 32055752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary retention in female OAB after intravesical Botox injection: who is really at risk?
    Miotla P; Cartwright R; Skorupska K; Bogusiewicz M; Markut-Miotla E; Futyma K; Rechberger T
    Int Urogynecol J; 2017 Jun; 28(6):845-850. PubMed ID: 27889830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin injections for adults with overactive bladder syndrome.
    Duthie J; Wilson DI; Herbison GP; Wilson D
    Cochrane Database Syst Rev; 2007 Jul; (3):CD005493. PubMed ID: 17636801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin injections for adults with overactive bladder syndrome.
    Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
    Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
    Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
    Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chapter 6: Practical aspects of administration of onabotulinumtoxinA.
    Rovner E
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S32-7. PubMed ID: 25042141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the ideal antibiotic prophylaxis for intravesically administered Botox injection? A comparison of two different regimens.
    Houman J; Moradzadeh A; Patel DN; Asanad K; Anger JT; Eilber KS
    Int Urogynecol J; 2019 May; 30(5):701-704. PubMed ID: 30074062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged urinary retention after intravesical botulinum injection for treatment of idiopathic detrusor overactivity.
    King AB; Rapp DE
    Can J Urol; 2011 Apr; 18(2):5657-9. PubMed ID: 21504656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Retention Rates After Intravesical OnabotulinumtoxinA for Idiopathic Overactive Bladder.
    Liberman D; Milhouse O; Johnson-Mitchell M; Siegel SW
    Female Pelvic Med Reconstr Surg; 2018; 24(6):404-407. PubMed ID: 28953573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB).
    Mohee A; Khan A; Harris N; Eardley I
    BJU Int; 2013 Jan; 111(1):106-13. PubMed ID: 22672569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children.
    Greer T; Abbott J; Breytenbach W; McGuane D; Barker A; Khosa J; Samnakay N
    J Pediatr Urol; 2016 Apr; 12(2):94.e1-6. PubMed ID: 26472538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
    Karsenty G; Denys P; Amarenco G; De Seze M; Gamé X; Haab F; Kerdraon J; Perrouin-Verbe B; Ruffion A; Saussine C; Soler JM; Schurch B; Chartier-Kastler E
    Eur Urol; 2008 Feb; 53(2):275-87. PubMed ID: 17988791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis.
    Lo CW; Wu MY; Yang SS; Jaw FS; Chang SJ
    Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
    Al Edwan GM; Mansi HH; Atta ONM; Shaath MM; Al Adwan R; Mahafza W; Afram KM; Ababneh O; Al Adwan D; Muheilan MM
    J Pediatr Surg; 2019 Mar; 54(3):595-599. PubMed ID: 29887168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center.
    Jiang YH; Ong HL; Kuo HC
    Neurourol Urodyn; 2017 Jan; 36(1):142-147. PubMed ID: 26417884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neuromodulation as a treatment for overactive bladder syndrome].
    Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
    Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
    Kantartzis K; Shepherd J
    Curr Opin Obstet Gynecol; 2012 Oct; 24(5):331-6. PubMed ID: 22922403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
    Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
    Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin A for the Treatment of Overactive Bladder.
    Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC
    Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.